At this time, Fareston (toremifene) tablets are available in brand-name form only. Although all of the patents for the drug have expired, no companies have chosen to make a generic Fareston product. It is unknown why this is the case, but it may be because the demand for this chemotherapy drug is so small that it would not be profitable to make a generic version.
Fareston® (toremifene citrate) is a prescription medication approved to treat postmenopausal women with metastatic (spreading) hormone receptor-positive breast cancer. It belongs to a group of medicines known as selective estrogen receptor modulators.
Fareston is made by Orion Oyj for ProStrakan, Inc. Although it is no longer protected from generic competition by patents, there are no generic versions of Fareston available in the United States.
Usually when a drug goes off-patent, companies begin to manufacture a generic version of it. In the case of Fareston, however, no manufacturer has chosen to make a generic version, even though it is no longer protected by patents.
It is not entirely clear why a manufacturer is not making a generic Fareston. The medication is not commonly used, so it could be that the demand for it is simply too small for a manufacturer to bother making a generic version. Because there are no clear reasons why a generic version is not yet available, it is difficult to say when, or even if, one will be available in the future.
No -- toremifene is the active ingredient in Fareston, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.